Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (2): 234-244    DOI: 10.31083/j.ceog.2021.02.2293
Systematic Review Previous articles | Next articles
Clinical efficacy of aortic balloon occlusion during caesarean section in patients with placenta accreta spectrum disorders: a systematic review and meta-analysis
Yu Huang1, Fang-Yuan Luo1, *()
1Department of Obstetrics and Gynecology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, No.32 West Second Section First Ring Road, 610041 Chengdu, Sichuan, China
Download:  PDF(823KB)  ( 81 ) Full text   ( 8 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Object: This systematic review and meta-analysis aim to examine evidence on the effectiveness and safety of aortic balloon occlusion (ABO) during caesarean deliveries in placenta accreta spectrum (PAS) disorders. Methods: MEDLINE, Science Citation Index, Elsevier, clinicaltrials.gov, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for articles dated from database inception to February 2020. The primary outcomes were intraoperative blood loss volume (BLV) and hysterectomy rate. Results: Of the 793 articles, 11 were included in this study, with a total of 915 patients. Of the 535 patients who underwent ABO, 48 (9%) had placenta creta; 309 (57%), placenta increta; and 124 (23%), placenta percreta. Meta-analysis showed that ABO significantly reduced BLV and blood transfused volume (P < 0.001), and reduced the rate of hysterectomy (P < 0.001). The overall catheter-related complication rate was 3.36%. The primary outcomes were available for 60 patients with placenta percreta. Meta-analysis of these patients showed ABO was associated with a decrease in BLV (P < 0.001), but not a statistically significant reduction in hysterectomy (P = 0.48). Conclusions: ABO is effective at controlling haemorrhage and reducing the need for hysterectomy in PAS disorders, but it did not appear to be effective for uterine preservation in patients with placenta percreta.
Key words:  Aorta      Balloon occlusion      Placenta accreta      Placenta percreta      Caesarean section     
Submitted:  13 September 2020      Revised:  07 November 2020      Accepted:  13 November 2020      Published:  15 April 2021     
Fund: 
2018SZ0230/Key projects of Sichuan Science and Technology Department
*Corresponding Author(s):  Fang-Yuan Luo     E-mail:  20180299120030@stu.swmu.edu.cn

Cite this article: 

Yu Huang, Fang-Yuan Luo. Clinical efficacy of aortic balloon occlusion during caesarean section in patients with placenta accreta spectrum disorders: a systematic review and meta-analysis. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 234-244.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2021.02.2293     OR     https://ceog.imrpress.com/EN/Y2021/V48/I2/234

[1] Shi-Fu Hu, Ying-Ying Wang, Yan-Qing Wu, Qiong Yu. Timing of prophylactic antibiotic use during elective caesarean section: a meta-analysis of randomised controlled trials[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 31-36.
[2] Dubravko Habek, Matija Prka, Anto Čartolovni, Anis Cerovac, Domagoj Dokozić. Caesarean section between doctrine to heresis. Medicoethical and deontological view of caesarology: an opinion[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 1-4.
[3] G. Garuti, E. Castellacci, S. Calabrese, S. Calzolari. Hysteroscopic removal of retained products of conception with enhanced vascularity: a study of reliability[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 472-477.
[4] K. Tamura, H. Takahashi, S. Uchida, M. Ogoyama, R. Usui, S. Matsubara. Intrauterine balloon failure: unrecognized placenta accreta spectrum disorders[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 405-408.
[5] Z.R. Zheng, X. Xie, Y. Hou, P. Xie, X. Yu, L. Xie. Intraoperative infrarenal aortic balloon occlusion in pregnancies with placenta accreta, increta, and percreta[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 704-708.
[6] B. Díaz-Rabasa, R. Crespo Esteras, A. Agustín-Oliva, R.A. Laborda Gotor, P. Tobías González, C. De Bonrostro Torralba, S. Castán Mateo. Has advanced maternal age a real impact on intrapartum caesarean rate?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 55-59.
[7] X.W. Sun, X.M. Bai, Q. Chen, J.F. Shen, L. Yang, J.Y. Zhang, X.S. Gu, Q. Yuan, J. Jing, Y. Jin. Preset catheter sheaths for uterine arterial embolization in the cesarean section of pernicious preplacental placenta: its application[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 108-112.
[8] Jing Fu, Na Hu, Lin Qiao, Qiang Yao. Cornual pregnancy with placenta percreta and uterine rupture at 19 weeks' gestation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 141-142.
[9] A. Tsiola, D. Marioli, I. Papadimitriou, V. Tsapanos, N. A. Georgopoulos. Increased kisspeptin mRNA expression derived from abnormally adhered placenta: compensatory inhibition of abnormal placental invasion?[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 204-208.
[10] A.S. Adlan, M.F. Zainal Abidin, C.C.W. Yim. Difference in outcomes of category 1 caesarean section patients in relation to type of anaesthesia administered: a tertiary university hospital experience[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 245-248.
[11] H. Kyozuka, K. Takiguchi, A. Owada, Y. Endo, M. Kojima, S. Suzuki, K. Fujimori. Two cases of placenta accreta with conservative management[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 283-286.
[12] S. Aslam, D. Al-Jaroudi. Women's involvement with the decision of caesarean section and their degree of satisfaction[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(1): 88-92.
[13] A. Okada, K. Tanaka, K. Kajitani, S. Nishimoto, H. Nakamura, O. Nakamoto. Near-infrared spectroscopy during cesarean section with common iliac artery balloon occlusion for total placenta previa: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(1): 112-114.
[14] B. Tuncali. A rare cause of intractable tachycardia during caesarean section: acute cannabis use[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(5): 804-805.
[15] D.R. Listijono, S.C. Chuah, F. Rahimpanah. Management of placenta accreta in an Australian tertiary referral centre: a ten-year experience[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(3): 374-378.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9 -21 .
[3] Ibrahim Sidiqi, Patrick Alexander. Current Advances in Endovascular Therapy for Infrapopliteal Artery Disease[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 36 -50 .
[4] Prakash C. Deedwania. Management of Patients With Stable Angina and Type 2 Diabetes[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 105 -113 .
[5] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38 -46 .
[6] Sophie Mavrogeni, Fabrizio Cantini, Gerald M. Pohost. Systemic Vasculitis: An Underestimated Cause of Heart Failure—Assessment by Cardiovascular Magnetic Resonance[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 49 -55 .
[7] Michael A. Weber. The Effects on Dementia of Long-Term Treatment of Hypertension[J]. Reviews in Cardiovascular Medicine, 2003, 4(3): 197 -198 .
[8] Steven V. Edelman. The Role of the Thiazolidinediones in the Practical Management of Patients With Type 2 Diabetes and Cardiovascular Risk Factors[J]. Reviews in Cardiovascular Medicine, 2003, 4(S6): 29 -37 .
[9] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[10] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .